Published in Head Neck on May 01, 2004
Translational control in cancer. Nat Rev Cancer (2010) 4.59
The translation factor eIF6 is a Notch-dependent regulator of cell migration and invasion. PLoS One (2012) 0.84
The biological roles of ITGB4BP and its potential effect on fibrosis. Int J Burns Trauma (2011) 0.78
EIF6 over-expression increases the motility and invasiveness of cancer cells by modulating the expression of a critical subset of membrane-bound proteins. BMC Cancer (2015) 0.77
Functional analysis of a novel glioma antigen, EFTUD1. Neuro Oncol (2014) 0.75
The role of eukaryotic translation initiation factor 6 in tumors. Oncol Lett (2017) 0.75
Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol (2006) 5.58
MicroRNA inhibition of translation initiation in vitro by targeting the cap-binding complex eIF4F. Science (2007) 4.33
The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest (2009) 3.34
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest (2010) 3.11
Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat. Nature (2012) 3.08
Release of eIF6 (p27BBP) from the 60S subunit allows 80S ribosome assembly. Nature (2003) 3.05
Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci (2002) 2.40
Alpha(v)beta3 integrin expression up-regulates cdc2, which modulates cell migration. J Cell Biol (2003) 1.97
Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood (2005) 1.92
The MSP receptor regulates alpha6beta4 and alpha3beta1 integrins via 14-3-3 proteins in keratinocyte migration. Dev Cell (2003) 1.91
Regulation of survivin function by Hsp90. Proc Natl Acad Sci U S A (2003) 1.86
Eukaryotic initiation factor 6 is rate-limiting in translation, growth and transformation. Nature (2008) 1.85
Regulation of microtubule stability and mitotic progression by survivin. Cancer Res (2002) 1.74
Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. Proc Natl Acad Sci U S A (2006) 1.69
IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood (2008) 1.55
Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat Med (2009) 1.54
Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein. FASEB J (2006) 1.50
In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia. Proc Natl Acad Sci U S A (2008) 1.48
Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. Blood (2012) 1.46
Emx2 and Pax6 control regionalization of the pre-neuronogenic cortical primordium. Cereb Cortex (2002) 1.45
Nuclear myosin VI enhances RNA polymerase II-dependent transcription. Mol Cell (2006) 1.39
Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. Hum Mol Genet (2011) 1.39
Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood (2010) 1.33
Maturing dendritic cells depend on RAGE for in vivo homing to lymph nodes. J Immunol (2008) 1.32
A dynamic podosome-like structure of epithelial cells. Exp Cell Res (2004) 1.25
Eukaryotic initiation factor 6 mediates a continuum between 60S ribosome biogenesis and translation. EMBO Rep (2009) 1.20
Conversion of cerebral cortex into basal ganglia in Emx2(-/-) Pax6(Sey/Sey) double-mutant mice. Nat Neurosci (2002) 1.19
Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. Blood (2011) 1.19
Mitochondrial ferritin expression in adult mouse tissues. J Histochem Cytochem (2007) 1.17
Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. J Immunol (2006) 1.16
Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain (2003) 1.15
PKCbetaII modulates translation independently from mTOR and through RACK1. Biochem J (2008) 1.15
Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models. Mol Ther (2009) 1.15
Podosomes as smart regulators of cellular adhesion. Eur J Cell Biol (2005) 1.13
Targeted inactivation of the COP9 signalosome impairs multiple stages of T cell development. J Exp Med (2008) 1.08
Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer. Nat Methods (2013) 1.08
Up-regulation of CD1d expression restores the immunoregulatory function of NKT cells and prevents autoimmune diabetes in nonobese diabetic mice. J Immunol (2004) 1.07
Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects. Blood (2006) 1.04
VE-cadherin expression and clustering maintain low levels of survivin in endothelial cells. Am J Pathol (2004) 1.03
Prognostic relevance of CD105+ microvessel density in HNSCC patient outcome. Oral Oncol (2005) 1.03
Association between hypermethylated tumor and paired surgical margins in head and neck squamous cell carcinomas. Clin Cancer Res (2007) 1.02
Fibronectin controls cap-dependent translation through beta1 integrin and eukaryotic initiation factors 4 and 2 coordinated pathways. Proc Natl Acad Sci U S A (2005) 1.01
Antidepressants act directly on astrocytes: evidences and functional consequences. Eur Neuropsychopharmacol (2012) 1.00
Differential regulation of the zebrafish orthopedia 1 gene during fate determination of diencephalic neurons. BMC Dev Biol (2006) 1.00
EVA regulates thymic stromal organisation and early thymocyte development. Biochem Biophys Res Commun (2007) 0.99
Ferroportin is a monomer in vivo in mice. Blood Cells Mol Dis (2005) 0.98
Impairment of cytoplasmic eIF6 activity restricts lymphomagenesis and tumor progression without affecting normal growth. Cancer Cell (2011) 0.98
AAV6-mediated systemic shRNA delivery reverses disease in a mouse model of facioscapulohumeral muscular dystrophy. Mol Ther (2011) 0.97
Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck (2007) 0.96
Interobserver variability of colposcopic interpretations and consistency with final histologic results. J Low Genit Tract Dis (2004) 0.96
Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context. Mol Cancer (2008) 0.95
RACK1 depletion in a mouse model causes lethality, pigmentation deficits and reduction in protein synthesis efficiency. Cell Mol Life Sci (2012) 0.95
The C-terminal domain of the transcriptional corepressor CtBP is intrinsically unstructured. Protein Sci (2006) 0.92
Serological immunoreactivity against colon cancer proteome varies upon disease progression. J Proteome Res (2008) 0.92
beta-carotene supplementation in patients radically treated for stage I-II head and neck cancer: results of a randomized trial. Oncol Rep (2003) 0.91
Translational control by 80S formation and 60S availability: the central role of eIF6, a rate limiting factor in cell cycle progression and tumorigenesis. Cell Cycle (2011) 0.90
Microenvironmental control of malignancy exerted by RNASET2, a widely conserved extracellular RNase. Proc Natl Acad Sci U S A (2010) 0.90
Selective ascorbate toxicity in malignant mesothelioma: a redox Trojan mechanism. Am J Respir Cell Mol Biol (2010) 0.90
Fowlpox-based survivin vaccination for malignant mesothelioma therapy. Int J Cancer (2013) 0.89
Sen34p depletion blocks tRNA splicing in vivo and delays rRNA processing. Biochem Biophys Res Commun (2005) 0.88
Docetaxel and vinorelbine: an effective regimen in recurrent squamous cell esophageal carcinoma. Med Oncol (2003) 0.88
Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. J Immunol (2013) 0.86
Eukaryotic ribosomes host PKC activity. Biochem Biophys Res Commun (2008) 0.86
Pink1-deficiency in mice impairs gait, olfaction and serotonergic innervation of the olfactory bulb. Exp Neurol (2012) 0.85
Postoperative adjuvant chemoradiotherapy in older patients with head and neck cancer. Arch Otolaryngol Head Neck Surg (2004) 0.85
Tagging of functional ribosomes in living cells by HaloTag® technology. In Vitro Cell Dev Biol Anim (2010) 0.85
Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer (2002) 0.85
GABP complex regulates transcription of eIF6 (p27BBP), an essential trans-acting factor in ribosome biogenesis. FEBS Lett (2006) 0.84
Induction of HIV-blocking anti-CCR5 IgA in Peyers's patches without histopathological alterations. J Virol (2014) 0.84
13-cis retinoic acid in head and neck cancer chemoprevention: results of a randomized trial from the Italian Head and Neck Chemoprevention Study Group. Oncol Rep (2004) 0.84
Massive apoptosis erodes nasal mucosa of cocaine abusers. Am J Rhinol (2006) 0.84
Sensitivity of global translation to mTOR inhibition in REN cells depends on the equilibrium between eIF4E and 4E-BP1. PLoS One (2011) 0.84
Epigallocatechin-3-gallate induces mesothelioma cell death via H2 O2 -dependent T-type Ca2+ channel opening. J Cell Mol Med (2012) 0.83
Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer. J Nucl Med (2013) 0.82
Playing a brass instrument after total laryngectomy: a case report. Head Neck (2009) 0.82
Impact of lipid raft integrity on 5-HT3 receptor function and its modulation by antidepressants. Neuropsychopharmacology (2010) 0.82
Cardiotoxicity after low-dose chloroquine antimalarial therapy. Heart Vessels (2009) 0.82
Polypoid atrial myxoma. J Cardiovasc Med (Hagerstown) (2012) 0.81
Prolonged islet allograft survival in diabetic mice upon macrophage depletion by clodronate-loaded erythrocytes. Transplantation (2008) 0.81
Preclinical demonstration of synergistic Active Nutrients/Drug (AND) combination as a potential treatment for malignant pleural mesothelioma. PLoS One (2013) 0.80
Spreading of mesothelioma cells is rapamycin-sensitive and requires continuing translation. J Cell Biochem (2009) 0.80
Histamine inhalation challenge in recurrent uvula angioedema. J Allergy Clin Immunol (2003) 0.80
Field effect in oral precancer as assessed by DNA flow cytometry and array-CGH. J Oral Pathol Med (2011) 0.79
Selective preservation of bone marrow mature recirculating but not marginal zone B cells in murine models of chronic inflammation. PLoS One (2010) 0.79
Docetaxel, carboplatin and concomitant radiotherapy for unresectable squamous cell carcinoma of the head and neck: pharmacokinetic and clinical data of a phase I-II study. Am J Clin Oncol (2004) 0.79
Formation of nuclear matrix filaments by p27(BBP)/eIF6. Biochem Biophys Res Commun (2002) 0.79
Constitutive expression of interleukin-18 in head and neck squamous carcinoma cells. Head Neck (2004) 0.79
Chromosomal aberrations and aneuploidy in oral potentially malignant lesions: distinctive features for tongue. BMC Cancer (2011) 0.79
A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer. Invest New Drugs (2014) 0.78
BDNF binding to truncated trkB.T1 does not affect gene expression. Neuroreport (2002) 0.78